<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003619</url>
  </required_header>
  <id_info>
    <org_study_id>AUH-MCP-70612-01</org_study_id>
    <secondary_id>CDR0000066698</secondary_id>
    <secondary_id>AUH-MCP-70612-02P</secondary_id>
    <secondary_id>NCI-V98-1485</secondary_id>
    <nct_id>NCT00003619</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia</brief_title>
  <official_title>A Phase I/II Combination Study of Topotecan, Fludarabine, Cytosine Arabinoside and G-CSF (T-FLAG) Induction Therapy in Patients With Poor Prognosis AML, MDS and Relapsed/Refractory ALL Followed by Maintenance of Either PBSC Transplant or 13 Cis-Retinoic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drexel University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to
      give higher doses of chemotherapy drugs and kill more cancer cells. Isotretinoin may help
      cancer cells develop into normal white blood cells.

      PURPOSE: Phase I/II trial of topotecan, fludarabine, cytarabine, and filgrastim followed by
      peripheral stem cell transplantation or isotretinoin in treating patients who have acute
      myeloid leukemia, myelodysplastic syndrome, or recurrent or refractory acute lymphocytic
      leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the safety of topotecan in combination with fludarabine, cytarabine,
      and filgrastim (FLAG) in patients with poor prognosis acute myeloid leukemia, myelodysplastic
      syndrome, or recurrent or refractory acute lymphocytic leukemia. II. Determine the maximum
      tolerated dose of topotecan in the FLAG regimen in these patients. III. Assess the complete
      remission rates in patients treated with this regimen.

      OUTLINE: Patients with complete response proceed to further therapy according to age. 65 and
      under: Patients receive etoposide by IV continuously for 5 days, cytarabine IV over 2 hours
      every 12 hours for 4 days, and filgrastim (G-CSF) subcutaneously. Peripheral blood stem cells
      (PBSC) are then harvested. Patients then receive oral busulfan every 6 hours on days -7 to -4
      and etoposide IV over 10 hours on day -3. PBSC are reinfused on day 0. Over 65: Patients
      receive oral isotretinoin and vitamin E daily. Treatment continues in the absence of disease
      progression or unacceptable toxicity. Patients are followed every month for 1 year and then
      every 3 months thereafter.

      PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study within 3-4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1998</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Thrombocytopenia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin E</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotretinoin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven poor prognosis acute myeloid leukemia (AML),
        myelodysplastic syndrome (MDS), or recurrent/refractory acute lymphocytic leukemia,
        including: Myelodysplastic syndrome (MDS) stages B and C Refractory anemia, refractory
        anemia with ringed sideroblasts, or refractory anemia with excess blasts (between 5% and
        20% myeloblasts) MDS with increased erythroblasts or monocytoblasts of no greater than 20%
        MDS in transformation (between 20% to 30% myeloblasts) or acute nonlymphoblastic leukemia
        (at least 30% myeloblasts) Chronic myelomonocytic leukemia Poor prognosis refractory or
        recurrent acute myeloid leukemia after complete response Secondary or therapy related AML
        or MDS AML blastic crisis of chronic myelogenous leukemia or other myeloproliferative
        disorders such as polycythemia vera, essential thrombocytopenia, or agnogenic myeloid
        metaplasia

        PATIENT CHARACTERISTICS: Age: 19 to 90 Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT or
        SGPT less than 2.0 times upper limit of normal Renal: Normal serum creatinine
        Cardiovascular: No congestive heart failure No symptomatic ischemic heart disease Other:
        Not pregnant or nursing Fertile patients must use effective contraception HIV negative No
        uncontrolled infection No poorly controlled diseases (e.g., diabetes, systemic lupus
        erythematosus) No history of psychiatric disorders No other malignancies within the past 5
        years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of
        the cervix No concurrent severe medical problems No history of allergic reaction to
        topotecan and its derivatives

        PRIOR CONCURRENT THERAPY: Biologic therapy: No other concurrent immunotherapy Chemotherapy:
        No prior topotecan At least 4 weeks since prior chemotherapy No other concurrent
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No concurrent radiotherapy
        Surgery: Not specified Other: No other investigational drugs within 30 days of study No
        other concurrent investigational therapy except for basal cell skin cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel C. Besa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Drexel University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Besa E, Maiale C, Liman D, et al.: Early data on a new combination chemotherapy using topotecan, fludarabine, ARA-C and G-CSF for aggressive myelodysplastic syndromes in the elderly. [Abstract] Leuk Res 23 (Suppl 1): A-191, S72, 1999.</citation>
  </results_reference>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2004</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

